Nurix director awarded options on 31,250 shares

Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock.

Rhea-AI Filing Summary

Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. All 31,250 underlying shares are reported as held directly after this award.

The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, assuming Mr. Saltzman continues to provide service to Nurix through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 31,250 shares

Grant/Award 1 txn

Insider Saltzman Edward C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Option grant size: 31,250 shares Exercise price: $15.86 per share Total derivative shares after grant: 31,250 shares +2 more

5 metrics

Option grant size 31,250 shares Director stock option underlying common stock

Exercise price $15.86 per share Option strike price for Nurix common stock

Total derivative shares after grant 31,250 shares Director’s holdings of this option after transaction

Option expiration date May 14, 2036 End of exercise period for the stock option

Latest vesting date May 15, 2027 Latest possible full vesting date, subject to service

Key Terms

Director Stock Option, exercise price, vesting, annual meeting of the Issuer's stockholders, +1 more

5 terms

Director Stock Option financial

"security_title: "Director Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "15.8600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests as to 100% of the award on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders..."

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nurix Therapeutics (NRIX) director Edward C. Saltzman report on this Form 4?

Edward C. Saltzman reported receiving a stock option grant for 31,250 shares of Nurix common stock. The award is a compensation-related option, not an open-market trade, and represents a new derivative position tied to future service with the company.

How many Nurix (NRIX) shares are covered by Saltzman’s new stock option grant?

The director stock option covers 31,250 underlying shares of Nurix common stock. Following the grant, the Form 4 shows 31,250 derivative securities held directly, all associated with this new option award reported in the filing.

What is the exercise price and expiration date of Edward Saltzman’s Nurix (NRIX) stock option?

The option has an exercise price of $15.86 per share and expires on May 14, 2036. This means Saltzman can buy Nurix common stock at $15.86 per share any time before the stated expiration date, once the option is vested.

When does Edward Saltzman’s Nurix (NRIX) director stock option vest?

The stock option vests 100% on the earlier of the next Nurix annual stockholder meeting or May 15, 2027. Vesting is conditioned on Saltzman continuing to provide service to Nurix through the applicable vesting date specified in the award’s terms.

Is the Form 4 for Nurix (NRIX) an insider purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market purchase. The A-code transaction is a director stock option award with a $15.86 exercise price, granted at no cash cost per share on the transaction date disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saltzman Edward C

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		(1)	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Edward C. Saltzman	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)